ACTRIMS 2018

Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Disability Linked to Fatty Acid Intake

Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Disability Linked to Fatty Acid Intake

By

Intakes of fats and types of fatty acids may affect disability severity in multiple sclerosis and neuromyelitis optica spectrum disorder.

Motivating Patients With Multiple Sclerosis May Improve Treatment Adherence, Outcomes

Motivating Patients With Multiple Sclerosis May Improve Treatment Adherence, Outcomes

By

Patients with multiple sclerosis who were motivated to remain adherent to treatment experienced overall better outcomes, including low relapse rates.

Screening for Comorbid Psychiatric Conditions in MS: Use of Validated Screening Tools

Screening for Comorbid Psychiatric Conditions in MS: Use of Validated Screening Tools

By

Barriers to using screening tools included lack of time and lack of insurance compensation.

Quality of Life in Relapsing vs Progressive Multiple Sclerosis

Quality of Life in Relapsing vs Progressive Multiple Sclerosis

By

Data obtained from the iConquerMS network highlight areas of quality of life that affect people with relapsing and progressive forms of MS and provide substantial basis for future research.

Examining the Relationship Between Vitamin D and Progressive Multiple Sclerosis

Examining the Relationship Between Vitamin D and Progressive Multiple Sclerosis

By

Vitamin D deficiency is a risk factor for multiple sclerosis.

Multiple Sclerosis Disability, Fatigue Reduced With Caffeine Intake

Multiple Sclerosis Disability, Fatigue Reduced With Caffeine Intake

By

The association suggests that caffeine consumption may play a protective role against multiple sclerosis-related disability.

Case Study: Improving Medication Adherence in MS Patients With Cognitive Deficits

Case Study: Improving Medication Adherence in MS Patients With Cognitive Deficits

By

Poor medication timing, incorrect doses, medication disorganization, and under- or over-medication are some of the medication adherence issues that can occur in patients with MS and cognitive symptoms.

Low Vitamin D in Obesity Not Associated With Risk for Multiple Sclerosis

Low Vitamin D in Obesity Not Associated With Risk for Multiple Sclerosis

By

Obesity-associated lowering of vitamin D levels may not mediate the putative causal relationship between obesity and multiple sclerosis.

Multiple Sclerosis Development in Two Teens After HPV Vaccination

Multiple Sclerosis Development in Two Teens After HPV Vaccination

By

Authors describe 2 case reports of MS in the pediatric population after administration of HPV vaccination.

Annualized Relapse Rates Compared Among 3 RRMS Therapies

Annualized Relapse Rates Compared Among 3 RRMS Therapies

By

The EFFECT study compared the efficacy of dimethyl fumarate vs other disease-modifying therapies, including fingolimod and glatiramer acetate in patients with relapsing-remitting multiple sclerosis.

Stable Disability in Progressive Multiple Sclerosis With Teriflunomide

Stable Disability in Progressive Multiple Sclerosis With Teriflunomide

By

A significant unmet need remains for an effective, well-tolerated, and convenient treatment for patients with progressive forms of MS.

Interferon β-1a Delays 6-Month Confirmed Disability Progression in RRMS

Interferon β-1a Delays 6-Month Confirmed Disability Progression in RRMS

By

The post-hoc analysis compared 6-month confirmed disability progression using patient data from PRISMS-2.

Safety, Efficacy of Fingolimod vs IFN- β-1a in Adolescents With RRMS

Safety, Efficacy of Fingolimod vs IFN- β-1a in Adolescents With RRMS

By

The randomized, double-blind PARADIGM study compared the safety and efficacy of fingolimod and interferon β-1a in teens with relapsing-remitting MS.

Small, Wearable Sensor Captures Progression, Limb Dysfunction in Multiple Sclerosis

Small, Wearable Sensor Captures Progression, Limb Dysfunction in Multiple Sclerosis

By

Application of technology developed in the gaming and computer control industry offers the opportunity to create new metrics with greater sensitivity and reproducibility.

Rebound Relapse in MS Seen After Discontinuing Fingolimod

Rebound Relapse in MS Seen After Discontinuing Fingolimod

By

Study authors emphasize the rebound relapse phenomenon as a potential complication in the safety of fingolimod.

Case: High-Dose Biotin Leading to Pseudohyperthyroidism in Multiple Sclerosis

Case: High-Dose Biotin Leading to Pseudohyperthyroidism in Multiple Sclerosis

By

A 55-year-old woman with multiple sclerosis and no history of thyroid disease developed lab abnormalities suggestive of thyrotoxicosis on routine testing.

Relapsing-Remitting Multiple Sclerosis: Maintaining No Evidence of Disease Activity With Natalizumab

Relapsing-Remitting Multiple Sclerosis: Maintaining No Evidence of Disease Activity With Natalizumab

By

Researchers aimed to determine the proportion of patients with early relapsing-remitting multiple sclerosis treated with natalizumab who achieve no evidence of disease activity at year 2.

Safety, Efficacy of Novel Oral Therapy for Relapsing MS

Safety, Efficacy of Novel Oral Therapy for Relapsing MS

By

Ozanimod decreased both T2 and T1 brain lesions and brain volume loss in patients with relapsing multiple sclerosis.

CRISP Trial Update: Suitability of Antipsychotic Medications for MS

CRISP Trial Update: Suitability of Antipsychotic Medications for MS

By

CRISP will determine the suitability of clozapine and risperidone as a treatment for progressive multiple sclerosis.

Exploring New Treatments for MS: Safety, Efficacy of Intravenous Cladribine

Exploring New Treatments for MS: Safety, Efficacy of Intravenous Cladribine

By

Researchers examined patients' disease course and the number of clinical attacks to determine the safety and efficacy of intravenous cladribine.

Sign Up for Free e-newsletters

CME Focus